Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing

Abstract excerpt

BACKGROUND: Tumor mutational burden (TMB) is emerging as a promising biomarker in immune checkpoint inhibitor (ICI) therapy. Despite whole-exome sequencing (WES) being the gold standard for quantifying TMB, TMB is determined by selected targeted panels in most cases, and WES-derived TMB data are lacking due to the greater cost and complexity. Determining TMB thresholds is another issue that needs attention....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Cancer Immunotherapy and Biomarkers
• Share to Colorectal Cancer Treatments and Studies